

CONTEST Study - Accuracy of contrast enhanced breast tomosynthesis: A comparison with digital mammography and breast MRI

Submission date 31/01/2018	Recruitment status No longer recruiting	☒ Prospectively registered ☒ Protocol
Registration date 12/02/2018	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 24/07/2026	Condition category Cancer	☐ Individual participant data

Plain English summary of protocol

Background and study aims

Breast cancer is the most common type of cancer in the UK. Some women, particularly younger women, have dense breast tissue, which makes it harder to spot cancers or areas of concern on a standard breast x-ray (mammogram). A new kind of x-ray called Contrast Enhanced Digital Breast Tomosynthesis (CE-DBT) may be particularly useful in these patients as it can highlight areas of concern even if the breasts are dense.

The aim of the study is to find out whether CE-DBT is better than a standard mammogram, and is as good as breast magnetic resonance imaging (MRI) to show tumour size.

Who can participate?

Women between the ages of 18-70 years old who have a high suspicion of breast cancer that can be operated on.

What does the study involve?

Participants receive a standard mammogram, and the new procedure CE-DBT. For this, participants have a special dye called contrast medium injected into the veins before the x-ray is taken. Some participants also have an MRI scan and all receive an ultrasound scan. If there are any areas of concern in the breast the participants may have a sample of cells taken by a needle biopsy.

Everybody completes a short questionnaire after the CE-DBT procedure and MRI scan to provide information about how they felt during each procedure.

What are the possible benefits and risks of participating?

Although it is not known, CE-DBT may provide better information than the standard tests potentially resulting in receiving the right diagnosis more quickly. There is also a chance that it will be easier to work out the most suitable treatment for a patient and increase certainty that no areas of concern have been missed if a participant's results show no serious breast problem. The injection needed for this test is generally very safe. However, with every injection of the dye, there is a very slight risk of a reaction. Some participants may develop a rash, and a few people may get a mild asthma attack. More serious reactions are very unusual.

The dye used for the test can affect the kidneys (less than 1 in 100 people). The test will not be offered if there are any risk factors or known kidney problems.

All x-rays involve radiation. The amount of radiation from a standard mammogram is small. It is similar to the amount of radiation received naturally from the environment over a period of a few months. The radiation dose from CE-DBT is higher than that of a standard mammogram, but still well within accepted safety guidelines.

Where is the study run from?
Ninewells Hospital Dundee (UK)

When is the study starting and how long is it expected to run for?
June 2017 to July 2023

Who is funding the study?
Chief Scientist Office (Scotland)

Who is the main contact?
1. Patsy Whelehan (Scientific/Public)
patsy.whelehan@nhs.scot
2. Dr Kulsam Ali (Public)
k.z.ali@dundee.ac.uk / 01382 383967

Contact information

Type(s)
Public

Contact name
Dr Kulsam Ali

Contact details
School of Medicine
Ninewells Hospital and Medical School
University of Dundee
Dundee
United Kingdom
DD1 9SY
+44(0)1382 383967
k.z.ali@dundee.ac.uk

Type(s)
Scientific

Contact name
Ms Patsy Whelehan

Contact details
School of Medicine
Ninewells Hospital and Medical School
University of Dundee
Dundee

United Kingdom
DD1 9SY
+44(0)1382 632813
patsy.whelehan@nhs.scot

Additional identifiers

Integrated Research Application System (IRAS)
237233

Protocol serial number
2017ON01

Study information

Scientific Title

CONTEST study: CONTRast Enhanced breaSt Tomosynthesis (CONTEST) in patients suspected of having breast cancer: a prospective comparison with digital mammography and breast MRI

Acronym
CONTEST

Study objectives

The aim of this study is to evaluate the performance of contrast-enhanced digital breast tomosynthesis (CE-DBT) in the identification and local staging of symptomatic breast cancer. We hypothesise that the diagnostic performance of CE-DBT will be significantly better than that of digital mammography (DM) and that it will not significantly differ from breast MRI in local staging and evaluation of local extent of breast cancer. The primary objective is to determine the incremental increase in sensitivity of CE-DBT over DM alone in women with symptoms/signs suspicious for breast cancer, the latter currently being standard of care.

Ethics approval required
Old ethics approval format

Ethics approval(s)
North of Scotland Research Ethics Service (REC2), 09/01/2018, ref: 17/NS/0123

Primary study design
Interventional

Study design
Prospective single-centre paired comparison study

Study type(s)
Diagnostic

Health condition(s) or problem(s) studied
Cancer

Interventions

All participants receive the equivalent of standard care, a Digital Mammogram (DM) and the experimental procedure which is the Contrast Enhanced Digital Breast Tomosynthesis (CE-DBT). Needle biopsy is carried out according to standard clinical practice if there are any areas of concern. All recruits with biopsy-proven breast cancer also undergo breast MRI but in a proportion this will be a study-specific procedure, and participants complete a short questionnaire after the CE-DBT and MRI to inform how they felt during the procedures.

Intervention Type

Procedure/Surgery

Primary outcome(s)

Sensitivity of CE-DBT compared with DM using surgical pathology as the gold standard.

Key secondary outcome(s)

1. Correlation of tumour size measurements with CE-DBT compared to MRI, using surgical pathology as the gold standard
2. Identification of multifocality with CE-DBT compared to MRI, using surgical pathology as the gold standard
3. Patient perspectives on the CE-DBT procedure is measured using a questionnaire after the procedure
4. Patient perspectives on the MRI scan is measured using a questionnaire after the procedure

Completion date

31/12/2023

Eligibility

Key inclusion criteria

1. Age 18 to 70 years inclusive
 2. Female
 3. Able to give informed consent
 4. Clinical examination findings suspicious or typical of operable breast cancer (E4/5)
- AND/OR
5. Ultrasound findings suspicious or typical of malignancy (U4/5)
 6. Able to give informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

18 Years

Upper age limit

70 Years

Sex

Female

Total final enrolment

87

Key exclusion criteria

1. History of prior iodinated contrast reaction
2. Iodine allergy
3. Severe asthma
4. Known renal impairment, strong risk factors for renal disease
5. Previous breast cancer surgery or implants
6. Current pregnancy, lactation
7. Inflammatory or clinically obvious locally advanced (inoperable) primary breast cancer who are likely to receive neoadjuvant chemotherapy (in these patients, imaging/pathological correlation will not be possible)
8. Contraindication to MRI
9. Obvious severe comorbidities precluding operative treatment
10. Otherwise deemed to be unsuitable by the clinical team

Date of first enrolment

01/05/2018

Date of final enrolment

31/05/2023

Locations**Countries of recruitment**

United Kingdom

England

Scotland

Wales

Study participating centre

Ninewells Hospital

Ninewells Avenue

Dundee

Scotland

DD1 9SY

Sponsor information

Organisation

University of Dundee and NHS Tayside

ROR

<https://ror.org/03h2bxq36>

Funder(s)

Funder type

Government

Funder Name

Chief Scientist Office (Scotland)

Results and Publications

Individual participant data (IPD) sharing plan

The data is held by the sponsor. After 5 years of publication, data can be requested from the chief investigator or sponsor. Sharing of data will be subject to a Material Transfer Agreement being in place.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		10/07/2026	24/07/2026	Yes	No
HRA research summary			28/06/2023	No	No
Protocol file	version 3.0	31/05/2021	05/09/2022	No	No